Health CareCompany Update
Clarity Pharmaceuticals (ASX: CU6) Doses 383 Patients in Phase III CLARIFY Trial
Clarity Pharmaceuticals has dosed the planned 383 participants in its registrational Phase III CLARIFY trial. Topline results are expected in the first half of 2027.
![[ASX: CU6] CLARITY PHARMACEUTICALS LTD a nuclear medicine imaging suite with a patient positioned on a PET and computed tomography scanner while](/media/hero/947149e8-382c-4465-8f3b-9c1756d78630/1793058820650-c93850ee-1536w.webp)
Listen to article
0:00 / 2:54Clarity Pharmaceuticals has dosed the planned 383 participants in its Phase III CLARIFY trial, completing a key enrolment step ahead of topline results expected in the first half of calendar 2027.
The registrational study is assessing Clarity’s copper-64 SAR-bisPSMA diagnostic imaging product in patients with untreated, high-risk prostate cancer who are proceeding to prostate removal and pelvic lymph node dissection. It is the company’s first Phase III registrational trial and is being conducted across the US and Australia.
CLARIFY’s results are intended to support a US Food and Drug Administration application for approval of copper-64 SAR-bisPSMA as a prostate cancer imaging agent before definitive therapy. However, the product remains unregistered, and its safety and efficacy have not been assessed by the FDA or Australia’s Therapeutic Goods Administration.
Accuracy under the microscope
The non-randomised, open-label trial will measure the product’s sensitivity and specificity in detecting prostate cancer within pelvic lymph nodes. Imaging results will be compared with histopathology from lymph nodes removed during surgery, providing confirmation of whether suspected lesions were cancerous.
Those endpoints will be assessed separately for scans performed between one and four hours after administration and scans conducted approximately 24 hours later. This will allow Clarity to evaluate both same-day and next-day imaging.
The trial’s design matters because accurately identifying cancer in pelvic lymph nodes can inform treatment decisions. Clarity said approved PSMA PET agents reported sensitivities of 27% to 40% in their respective pivotal Phase III studies for detecting pelvic lymph node metastases before prostatectomy. None reached their prespecified primary sensitivity thresholds, according to the company.
CLARIFY also allows direct comparison with standard-of-care PSMA imaging where those scans were performed.
Two pivotal readouts due in 2027
Topline CLARIFY data are scheduled for release in the first half of 2027 alongside results from AMPLIFY, Clarity’s other registrational Phase III study of copper-64 SAR-bisPSMA. AMPLIFY is evaluating the imaging agent in patients with biochemical recurrence of prostate cancer and has also completed recruitment.
Earlier evidence supporting CLARIFY came from the 30-patient Phase I PROPELLER trial. Clarity reported that same-day copper-64 SAR-bisPSMA imaging achieved approximately 30% greater lesion detection and two to three times higher tracer uptake and contrast than gallium-68 PSMA-11 imaging in the pre-prostatectomy setting.
The company has also observed improved diagnostic performance from next-day imaging compared with same-day imaging in its COBRA and Co-PSMA studies involving biochemical recurrence. Whether that benefit extends to newly diagnosed, high-risk patients is one of the questions CLARIFY is designed to assess.
Copper-64 SAR-bisPSMA combines two PSMA-targeting agents with Clarity’s proprietary sarcophagine technology, which holds the copper isotope within a cage-like chelator. The upcoming Phase III data will determine whether the earlier diagnostic findings translate into the evidence required for a US regulatory submission.
Latest CLARITY PHARMACEUTICALS LTD ASX Announcements
- 18 Nov 2026 · 4:30 pmSubstantial Holders
- 12 Nov 2026 · 10:17 amCompany Update
- 11 Nov 2026 · 5:20 pmSubstantial Holders
- 11 Nov 2026 · 10:07 amTrading Halt / Suspension
- 11 Nov 2026 · 9:51 amTrading Halt / Suspension
- 9 Nov 2026 · 5:42 pmSubstantial Holders
- 30 Oct 2026 · 3:40 pmQuarterly Reports
- 27 Oct 2026 · 9:14 amCompany Update
![[ASX: LDX] LUMOS DIAGNOSTICS HOLDINGS LIMITED a clinician in an urgent care examination room preparing a fingerstick blood sample beside a compact](/media/hero/14fdc9c1-090a-4cb4-838b-6ccac9e764af/1794196573830-a831dc31-640w.webp)
![[ASX: OCC] ORTHOCELL LIMITED a close-up composition of sustainably sourced pearl shells beside a small sample of processed bone graft biomaterial in](/media/hero/1d78f211-86f4-4939-97eb-81bda5f14669/1793764030563-b679e509-640w.webp)
![[ASX: CC5] CLEVER CULTURE SYSTEMS LIMITED a laboratory scientist loading culture plates into an automated analysis instrument within a clean pharmaceutical quality-control](/media/hero/8a1c5622-2122-437c-ac99-192f57d45b44/1793152635605-44fac865-640w.webp)
![[ASX: WCE] WEST COAST SILVER LIMITED a wide view of a diamond drill rig operating in the arid West Pilbara landscape south](/media/hero/cfccd740-5f90-4e54-9313-fc4a9c958e74/1794354529622-c28eff18-640w.webp)
![[ASX: FDC] FDC CONSOLIDATED HOLDINGS LIMITED a large Australian non-residential construction site with cranes, concrete structures and workers coordinating activity, shown in](/media/hero/86516878-cc39-4b24-ad9d-05705567e060/1794353703382-3fbd7e98-640w.webp)
![[ASX: CTN] CATALINA RESOURCES LTD a wide aerial view of the arid Badja Gold Project terrain in Western Australia’s Mid-West, showing historic](/media/hero/a4f6201c-c90f-4223-b253-7810ef792ab6/1794269645823-8fdfc691-640w.webp)